PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots:The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6BIn the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

VIEWPOINTS

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots: Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD)Erika also talked about how NeuroSphere Virtual Clinic is compatible with the deep brain stimulation (DBS) system The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…

BySenior EditorOctober 5, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2022

The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4BThe third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

BySenior EditorSeptember 29, 2022

TOP 20

Top 20 Medical Device Companies Based on 2021 Revenue

Despite the severe impact of the Covid-19 pandemic in 2020, the medical device market continued to emerge with patients' more significant needs and emerging diseases In 2021, the medical device markets continued to supply personal protective equipment for the pandemic and new technological developments. Medtronic remains at the top of the ledger with total revenue…

ByPrince GiriMay 12, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfoliosWhile top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

VIEWPOINTS

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs

In an interview with PharmaShots, Dr. Allen Burton, Medical Director of Abbott’s Neuromodulation Business shared his views on the US FDA approval for expanded MRI compatibility of Its Proclaim XR SCS DeviceShots:The US FDA has approved new expanded MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads. The Proclaim XR SCS System is an…

BySenior EditorApril 11, 2022

VIEWPOINTS

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care.Shots:A study published in the Journal of Primary Care and Community Health has shown that a new…

BySenior EditorOctober 13, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229MThe key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

VIEWPOINTS

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor's approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery.Shots:Abbott has received CE Mark approval for its latest-generation transcatheter aortic…

BySenior EditorSeptember 3, 2021

TOP 20

Top 20 Diagnostics Companies Based on 2020 Revenue

The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world's biggest diagnostics companies being thrust into the limelightSiemens Healthineers- GE Healthcare- Roche- and Abbott are the top players in the race of the global diagnostic companies. The companies are…

ByPrince GiriJune 10, 2021

PharmaShots’ Key Highlights of Fourth Quarter 2022

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

PharmaShots’ Key Highlights of Third Quarter 2022

Top 20 Medical Device Companies Based on 2021 Revenue

Top 20 BioPharma Companies based on 2021 Total Revenue

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

PharmaShots’ Key Highlights of Third Quarter 2021

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

Top 20 Diagnostics Companies Based on 2020 Revenue

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter